Paediatric tuberculosis in Singapore: a retrospective review

Sin Wee Loh,1,2 Koh Cheng Thoon,2,3,4 Natalie Woon Hui Tan,2,3,4,5 Jiahui Li,2,3 Chia Yin Chong2,3,4,5

ABSTRACT

Background Tuberculosis (TB) is a major cause of mortality and morbidity in the world. Each case represents ongoing transmission and has a significant public health burden. We aim to examine the clinical profile of paediatric TB and compare pulmonary TB (PTB) with extrapulmonary TB (EPTB) in Singapore.

Methods A retrospective study of patients admitted to KK Women’s and Children’s Hospital, Singapore from January 2008 to September 2017 with active TB was undertaken. The clinical characteristics and outcomes of patients with PTB and EPTB were compared.

Results Seventy-five patients were diagnosed as having active TB (49 (65%) with PTB and 26 (35%) with EPTB). Patients with EPTB were more likely than those with PTB to be younger (median age 5.1 (IQR 1.2–10.2) years vs 10.1 (IQR 3.5–13.5) years), immunodeficient (35% vs 6%), with a lower haemoglobin count (median 11.2 (IQR 10.2–11.9) g/dL vs 12.0 (IQR 10.5–13.9) g/dL), lower recovery rate (27% vs 57%) and required longer duration of treatment (median 12 (IQR 9–12) months vs 6 (IQR 6–9) months). Common clinical presentations involving a third of cases of TB. The proportion of EPTB to PTB has increased due to a decrease in PTB rates. However, little is known about the global impact of paediatric EPTB.

Conclusion EPTB is more common in the younger age group and is associated with a lower recovery rate.

INTRODUCTION

Tuberculosis (TB) remains a major cause of morbidity and mortality in the world. Following the introduction of the Singapore Tuberculosis Elimination Programme in 1997, the incidence of TB declined from 57 per 100 000 residents in the 1990s to a low of 35 per 100 000 residents in 2007. In 2016 the incidence of TB was 38.7 per 100 000 residents in Singapore; children aged <19 years contributed only 2.1% of the total TB population. The majority (84%) of cases had pulmonary TB (PTB) with or without extrapulmonary involvement, while the remainder (17%) had extrapulmonary TB (EPTB) exclusively.1

The presentation of TB in children can range from non-specific symptoms to a severe clinical presentation, which makes diagnosis challenging. Although PTB is the most common form, all other organs can be involved as well.2,3 Globally, in 2014 almost 10 million people developed TB, of which EPTB represented almost 15% of the overall cases of TB.4 In adults the proportion of EPTB to PTB has increased due to a decrease in PTB rates.5 However, little is known of the global impact of paediatric EPTB due to difficulties in paediatric TB case detection and low notification rates.6 The last published review of paediatric TB in Singapore was by Paul in 1967, which focused on the fatality of tuberculous meningitis. With the changing demographics in Singapore, a new review of paediatric TB is needed.7,8 The aims of this study were to examine the clinical profile and treatment outcomes of paediatric TB and to compare PTB with EPTB.

METHODS

Setting Kandang Kerbau (KK) Women’s and Children’s Hospital (KKH) is the largest tertiary paediatric hospital in Singapore with approximately 350 paediatric beds, and accounts for 54% of paediatric admissions nationally (based on market trends; Corporate Communications, KKH). We collected data on all
patients who were admitted for TB investigation in KKH from January 2008 to September 2017. Approval was obtained from the centralised institution review board of Singhealth Research.

**Patient identification and data collection**

A patient list with the code tuberculosis was generated using the International Classification of Disease (ICD9CM or ICD10AM from 2012 onwards). Patients who were treated for active TB were included, while latent TB cases were excluded. Data pertaining to demographic profile, clinical presentation, investigations and treatment of selected cases were collected from case notes, electronic records and the infectious disease database.

**Case definitions**

Both microbiologically proven cases and non-microbiologically proven cases were included. Microbiologically proven cases were defined as those with a positive TB culture and/or TB PCR. Non-microbiologically proven cases were defined as those with a negative TB culture or PCR but positive TB smear, tuberculin skin test, interferon gamma release assay (IGRA) in the presence of a clinical diagnosis of TB or suggestive chest X-ray (CXR). EPTB was defined as any active TB case involving organs other than the lungs and pleurae. Multiorgan TB was defined as active TB involving two or more organs and was considered EPTB. CNS TB (subset of EPTB) was defined as TB meningitis or meningoencephalitis.

Close contact was defined as living in the same household or in frequent contact with a case of smear-positive PTB. Immunodeficiency was either primary immune disorders or secondary to an underlying disease or immunosuppressive drugs. Definitions of symptoms were adapted from the South African Guidelines 20139:

- Significant cough was defined as cough duration of ≥14 days
- Significant fever was defined as temperature ≥38°C for ≥14 days
- Significant weight loss was defined as ≥1kg for ≥1 month. Weight loss was further expressed as a percentage of body weight at diagnosis
- Fatigue was defined as patient’s or parents’ complaint of reduced playfulness or lethargy

In our centre, the T-SPOT.TB assay (Oxford Immunotec, Abingdon, UK) is the preferred type of IGRA used for children aged ≥2 years because of the lower rate of indeterminate results compared with QuantiFERON-TB Gold and QuantiFERON-TB In-tube.10 A tuberculin skin test (TST) might be performed when the T-spot is not available (ie, out of office hours). A positive TST was defined as a reading of ≥10mm at 48 hours. All patients had CXR performed and reported by in-house radiologists. All our patients had microbiological investigations. Consecutive fluid specimens were sent for acid-fast bacilli (AFB) smear and culture, using the automated MGIT960 system for liquid growth and Lowenstein–Jensen slants for solid growth.10 11 Multidrug-resistant TB (MDR-TB) was defined as resistance to both rifampicin and isoniazid.

**Statistical analysis**

Analysis was carried out using SPSS Version 19 (IBM, Armonk, New York, USA). Categorical data were expressed as counts and percentages and continuous data were expressed as median and interquartile ranges (IQR). Differences between categorical data were analysed by χ² tests or Fisher’s exact test when cell sizes were less than 5. Differences between continuous data were analysed by the Mann–Whitney test. All statistical tests were two-tailed and a p value <0.05 was statistically significant.

**RESULTS**

Seventy-five patients were included, of which 49 (65%) had PTB and 26 (35%) had EPTB (5 lymphatic, 7 CNS, 1 pericardial, 2 gastrointestinal, 1 eye, 2 musculoskeletal and 8 multiorgan TB). All cases of CNS TB were TB meningitis. Of the eight patients with multiorgan TB, two had pulmonary and CNS involvement and one patient each had CNS and lymphatic involvement; gastrointestinal and musculoskeletal involvement; pulmonary and gastrointestinal involvement; pulmonary and lymphatic involvement; gastrointestinal, lymphatic and musculoskeletal involvement; and gastrointestinal and pulmonary involvement.

**Table 1** describes the differences between PTB and EPTB. Patients with EPTB were younger (median age 5.1 years (IQR 1.2–10.2) vs 10.1 years (IQR 3.5–13.5), p=0.03), were more likely to be immunodeficient (35% vs 6%, p<0.01) and had a lower haemoglobin level (median 11.2 g/dL (IQR 10.2–11.9) 12.0 g/dL (IQR 10.5–13.9), p=0.01). Common clinical presentations of both PTB and EPTB were significant fever (27%), cough (33%) and weight loss (32%). However, only 20 (27%) of our patients presented with ≥2 significant symptoms. Patients with PTB were more likely to have significant cough whereas those with EPTB were more likely to present with significant fever and/or lymphadenopathy (table 1). Twenty-eight patients (37%) had positive TB contact (26 household contacts and 2 school contacts). Only four patients (5%) had ≥2 significant symptoms and a positive contact history.

An abnormal CXR was found in 51 patients (68%) with the following changes: pulmonary infiltrates (n=24, 32%), hilar adenopathy (n=7, 9%), miliary (n=4, 5%), lobar collapse (n=3, 4%), pleural changes (n=2, 3%), cavitation (n=2, 3%), widened mediastinum (n=1, 1%) and a combination of these changes (n=8, 11%). Patients with PTB were more likely to have an abnormal CXR than those with EPTB (84% vs 39%, p<0.01). More than half of the patients with PTB and EPTB had microbiologically proven disease (53% and 73%, respectively). T-Spot was performed in 41 (55%) patients: 32 (78%) positive, 6 (15%) negative and 3 (7%) had microbiologically proven disease (53% and 73%, respectively). T-Spot was performed in 41 (55%) patients: 32 (78%) positive, 6 (15%) negative and 3 (7%)...
|                                | Pulmonary n=49 (%) | Extrapulmonary n=26 (%) | P values |
|--------------------------------|--------------------|--------------------------|----------|
| **Median age (years)**         | 10.1 (IQR 3.5–13.5) | 5.1 (IQR 1.2–10.2)       | 0.03     |
| **Gender**                     |                    |                          |          |
| Males                          | 25 (51)            | 14 (54)                  | 0.82     |
| Females                        | 24 (49)            | 12 (46)                  |          |
| **Nationality**                |                    |                          |          |
| Singapore residents            | 37 (76)            | 16 (62)                  | 0.21     |
| Non-Singapore residents        | 12 (24)            | 10 (38)                  |          |
| **Received BCG vaccine**       |                    |                          | 0.14     |
| Immunodeficient                | 3 (6)              | 9 (35)                   | <0.01    |
| Not immunodeficient            | 46 (94)            | 17 (65)                  |          |
| **Contact history**            |                    |                          |          |
| Positive contact               | 22 (45)            | 6 (23)                   | 0.06     |
| No contact history             | 27 (55)            | 20 (77)                  |          |
| **Symptoms**                   |                    |                          |          |
| Significant fever              | 9 (19)             | 11 (48)                  | 0.01     |
| Significant cough              | 22 (51)            | 3 (14)                   | <0.01    |
| Significant weight loss        | 18 (39)            | 6 (27)                   | 0.34     |
| Median weight loss (% body weight) | 10.6 (IQR 5.8–20.0) | 16.3 (IQR 13.6–40.6)   | 0.29     |
| **Fatigue**                    | 2 (4)              | 2 (8)                    | 0.60     |
| **Lymphadenopathy**            | 2 (4)              | 8 (31)                   | <0.01    |
| ≥2 symptoms stated above       | 14 (29)            | 5 (23)                   | 0.61     |
| No symptom stated above        | 22 (45)            | 11 (42)                  | 0.83     |
| **Haematological results**     |                    |                          |          |
| Median haemoglobin (g/dL)      | 12.0 (IQR 10.5–13.9) | 11.2 (IQR 10.2–11.9) | 0.03     |
| Median white blood cells (x10^9/L) | 11.2 (IQR 7.5–15.6) | 10.2 (IQR 7.6–12.0)    | 0.15     |
| Median platelet count (x10^9/L) | 376.5 (IQR 281.5–451.0) | 377.0 (IQR 339.5–507.0) | 0.38 |
| Median ESR (mm/hour)           | 40.0 (IQR 15.0–85.0) | 34.0 (IQR 19.0–54.5)   | 0.61     |
| Median CRP (mg/L)              | 36.0 (IQR 16.5–84.4) | 32.4 (IQR 8.6–69.3)    | 0.43     |
| **Immunological results**      |                    |                          |          |
| Positive TST                   | 20 (41)            | 6 (23)                   | 0.10     |
| Positive IGRA                  | 20 (41)            | 12 (46)                  | 0.80     |
| **Microbiological**            |                    |                          |          |
| Microbiologically proven       | 26 (53)            | 19 (73)                  | 0.10     |
| Not microbiologically proven   | 23 (47)            | 7 (27)                   |          |
| **Microbiological results**    |                    |                          |          |
| ≥1 site/sample positive AFB smear | 13 (27)            | 7 (28)                   | 0.89     |
| ≥1 site/sample positive AFB culture | 24 (49)            | 15 (58)                  | 0.47     |
| ≥1 site/sample positive TB PCR | 14 (40)            | 12 (60)                  | 0.15     |
| Abnormal CXR                   | 41 (84)            | 10 (39)                  | <0.01    |
| **Treatment outcome**          |                    |                          |          |
| Recovered                      | 28 (57)            | 7 (27)                   | 0.01     |
| Death                          | 2 (4)              | 4 (15)                   | 0.17     |
| Relapsed                       | 1 (2)              | 1 (4)                    | -        |

Continued
Table 1 Continued

| Sequelea | Pulmonary n=49 (%) | Extrapulmonary n=26 (%) | P values |
|----------|--------------------|-------------------------|----------|
|          | 10 (20)            | 9 (35)                  | 0.18     |
| Lost to follow-up | 8 (16) | 3 (12) | 0.73 |
| Still completing treatment | 0 (0) | 2 (8) | - |
| Median duration of treatment (months) | 6.0 (IQR 6.0–9.0) | 12.0 (IQR 9.0–12.0) | <0.01 |

AFB, acid-fast bacilli; CRP, C-reactive protein; CXR, chest X-ray; ESR, erythrocyte sedimentation rate; IGRA, interferon gamma release assay; TST, tuberculin skin test.

Table 2 Types of immunodeficiencies in pulmonary and extrapulmonary TB

| Types of immunodeficiencies | Pulmonary n=49 (%) | Extrapulmonary n=26 (%) |
|-----------------------------|--------------------|-------------------------|
| HIV                         | 2 (4)              | 2 (8)                   |
| Malignancy                  | 0 (0)              | 2 (8)†                  |
| Primary immune deficiency   | 0 (0)              | 2 (8)‡                  |
| Others                      | 1 (2)*             | 3 (12)§                 |

*Ebstein–Barr virus-related haemophagocytic lymphohistiocytosis.
†One medulloblastoma on chemotherapy, one neuroblastoma on chemotherapy.
‡Severe combined immunodeficiency.
§One Crohn’s disease on immunosuppressant, one juvenile idiopathic arthritis on biologics, one Mendelian susceptibility to mycobacterial disease.

Discussion

Our study compares the demographics, clinical spectrum, investigation results and outcomes of PTB and EPTB. The median age of patients with EPTB was significantly younger than those with PTB (median age 5.05 vs 10.10 years, p=0.03), which is similar to another study of paediatric TB. EPTB had a lower recovery rate and higher mortality, relapse and sequelae rates compared with PTB. Similar to other studies, this implies that younger children have a higher risk of serious TB. The mortality of TB meningitis from our review had decreased drastically from a peak of 60% in 1955. A mass BCG vaccination campaign, implemented in 1957, was one of the key interventions that led to a marked decrease in TB mortality rates, especially EPTB and for children aged <5 years. A retrospective paediatric study in China showed that EPTB was more prevalent in the BCG unvaccinated group (59% vs 41%, p=0.05); our small study failed to show any significant difference. This finding suggests that children who received BCG vaccination have less chance of contracting EPTB.

Children with TB rarely present with classical symptoms, as seen in a survey from a high burden community. This is similar to our study in which only 27% of patients presented with ≥2 out of five significant symptoms listed by the South African Society for Paediatric Infectious Diseases. Marais et al stated that the index of suspicion should be increased when symptoms such as prolonged cough for ≥2 weeks, significant weight loss and fatigue exist together with positive TB contact. Four (5%) of our patients with TB had ≥2 significant symptoms and a positive contact history. Nevertheless, available scoring systems should not be used for predicting paediatric TB infection as they lack sensitivity and specificity.

An abnormal CXR was seen in 68% of our patients, which was higher than a large-scale multicentre study conducted in India. This can be explained by significant variation between radiologists when interpreting paediatric CXR. Moreover, CXR had a high sensitivity but low specificity for detecting active TB, as many radiological changes seen in TB could be present in other infections.

A positive microbiological culture remains the gold standard for diagnosis of active TB, but is often limited by the prolonged turnover time. In this study the percentage
of patients with eventual positive TB culture (49.0% and 57.5%) was more than those with ≥1 positive AFB smears (26.5% and 28.0%) in both the PTB and EPTB groups, which could lead to a delay in identification and treatment of active TB disease. Our higher TB culture rates compared with 15.7% in China and 34% in the USA could be due to more aggressive sampling methods or different culture methods.12 23

Immunological investigations such as TST and IGRA can aid in the diagnosis of TB, but each has its own limitations. In children aged <4 years, TSpot is preferred as it has a lower rate of indeterminate results compared with the QuantiFERON-TB test.24 While IGRA and TST are good predictors of latent TB infection, their sensitivity for active TB infection is much more limited.25 26 Regardless of TST or IGRA results, treatment for TB should not be delayed if factors are strongly suggestive of TB (contact history, radiological and microbiological).27

The limitations of this study were the small sample size and its retrospective nature. It was not powered to correlate the effect of age, gender and symptoms with laboratory results. This study only included patients who received inpatient treatment for TB in KKH, potentially missing the less severe group who received outpatient therapy.

CONCLUSION
EPTB is more common in the younger age group and is associated with a lower recovery rate. As TB culture has a long turnover time, treatment for TB should not be delayed if other factors are strongly suggestive of TB. Clinicians should have a high index of suspicion for EPTB and should pay special attention to the younger age group.

REFERENCES
1. Ministry of Health. Communicable Diseases Surveillance in Singapore. Singapore, 2016:103–15.
2. Yang Z, Kong Y, Wilson F, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004;38:199–205.
3. Gonzalez OY, Adams G, Teeter LD, et al. Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis 2003;7:1178–85.
4. World Health Organization. Global Tuberculosis Report 2015. Geneva, 2015.
5. Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. Euro Surveill 2013;18 3 4.
6. Santiago-Garcia B, Blázquez-Gamero D, Baquero-Artigao F, et al. Pediatric extrapulmonary tuberculosis: clinical spectrum, risk factors and diagnostic challenges in a low prevalence region. Pediatr Infect Dis J 2016;35:1175–81.
7. Paul FM. Tuberculosis in B.C.G. vaccinated children in Singapore. Arch Dis Child 1961;36:530–6.
8. Paul F. Tuberculosis meningitis in children in the Department of Paediatrics over a ten-year period. Singapore Med J 1967;8:102–10.
9. Moore D, Schaaf H, Nuttall J, et al. Childhood tuberculosis guidelines of the Southern African Society for Paediatric Infectious Diseases (SASPID), S Afr J Infect Dis 2009;24:57–68.
10. Chee CS, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol 2008;46:1935–40.

Contributors SWL, KCT and CYC were involved in the design of the study. SWL was in charge of acquisition of data, interpretation of data and drafting of the manuscript. KCT, NWHT, JL and CYC were involved in revising and approval of the final manuscript. CYC provided mentorship throughout the project.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
11. Chan DS, Choy MY, Wang S, et al. An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). J Med Microbiol 2008;57:1220–2.

12. Wu XR, Yin QQ, Jiao AX, et al. Pediatric tuberculosis at Beijing Children’s Hospital: 2002-2010. Pediatrics 2012;130:e1433.

13. Moyo S, Verver S, Mahomed H, et al. Age-related tuberculosis incidence and severity in children under 5 years of age in Cape Town, South Africa. Int J Tuberc Lung Dis 2010;14:149–54.

14. Newton SM, Brent AJ, Anderson S, et al. Paediatric tuberculosis. Lancet Infect Dis 2008;8:498–510.

15. Chew CH, Hu PY. BCG programme in the Republic of Singapore. Singapore Med J 1974;15:241–5.

16. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698–702.

17. Marais BJ, Obihara CC, Gie RP, et al. The prevalence of symptoms associated with pulmonary tuberculosis in randomly selected children from a high burden community. Arch Dis Child 2005;90:1166–70.

18. Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 2006;118:e1350–e1359.

19. Hesseling AC, Schaaf HS, Gie RP, et al. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002;6:1038–45.

20. Swaminathan S, Datta M, Radhamani MP, et al. A profile of bacteriologically confirmed pulmonary tuberculosis in children. Indian Pediatr 2008;45:743–7.

21. Hoog AH, Meme HK, van Deutekom H, et al. High sensitivity of chest radiograph reading by clinical officers in a tuberculosis prevalence survey. Int J Tuberc Lung Dis 2011;15:1308–14.

22. Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl 2014;91:32–40.

23. Winston CA, Menzies HJ. Pediatric and adolescent tuberculosis in the United States, 2008-2010. Pediatrics 2012;130:e1425–e1432.

24. Bergamini BM, Losi M, Vaienti F, et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection in children and adolescents. Pediatrics 2009;123:e419–e424.

25. Connell T, Tebruegge M, Ritz N, et al. Interferon-gamma release assays for the diagnosis of tuberculosis. Pediatr Infect Dis J 2009;28:758–9.

26. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340–54.

27. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med Overseas Ed 2012;367:348–61.